Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The FDA now requires every GLP-1 receptor agonist — including Ozempic, Wegovy, Mounjaro, and Zepbound — to carry a warning about a rare but potentially permanent eye condition called NAION. The condition causes sudden, painless vision loss in one eye, often noticed upon waking. Clinicians are urged to refer suspected cases to an ophthalmologist promptly and consider discontinuing the drug if NAION develops.
The FDA announced on November 9, 2026, that all GLP-1 receptor agonists (GLP-1 RAs) — including semaglutide, tirzepatide, liraglutide, dulaglutide, and the newly approved orforglipron — must now carry a class-wide label warning about nonarteritic anterior ischemic optic neuropathy (NAION). The requirement applies regardless of whether the drug is prescribed for diabetes or weight management.
NAION occurs when blood flow to the optic nerve is reduced, causing sudden, painless vision loss — typically in one eye and often noticed upon waking. Vision loss is frequently permanent, and a prior episode raises the risk of it occurring in the other eye. The FDA's decision was informed by a pooled meta-analysis of 126 GLP-1 RA trials, a Sentinel System cohort study, and a landmark 2024 study from Massachusetts Eye and Ear that found significantly elevated NAION risk with semaglutide.
By the Numbers:
Why it matters: With millions of patients on GLP-1 medications globally, even a rare risk carries significant real-world impact. Clinicians should counsel patients to report sudden vision changes immediately and refer suspected NAION cases to an ophthalmologist without delay.
